HIV–Associated Lipodystrophy: Pathogenesis, Prognosis, Treatment, and Controversies
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Potent antiretroviral agents markedly suppress HIV and have dramatically improved the clinical course, prognosis, and survival of HIV-infected patients. Unfortunately, highly active antiretroviral therapy is often compromised by metabolic complications, including insulin resistance, dyslipidemia, and fat redistribution. Together these changes have been termed the HIV-lipodystrophy syndrome, which is estimated to affect a majority of patients treated with potent combination antiretroviral therapy. Routine testing of fasting glucose is recommended for all HIV-infected patients, particularly those who are obese, have a family history of diabetes mellitus, or are receiving protease inhibitor therapy. Preliminary investigations have demonstrated the potential utility of insulin-sensitizing agents and lipid-lowering therapies to ameliorate these metabolic disturbances. Patients with HIV infection who demonstrate fat redistribution and develop hyperinsulinemia and dyslipidemia may be at increased risk of cardiovascular disease. However, the long-term effects on cardiovascular disease have not yet been determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Carr, A., Samaras, K., Chisholm, D. J., & Cooper, D. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03391-1 · Cited by 1,065 · cited 2×
“Furthermore, sequence homology of the PIs to lipoprotein receptor-like protein (LRP) suggests a potential effect of the PI’s on lipid clearance, but the clinical importance of this observation remains unknown (23).”
BackgroundDoes central obesity reflect “Cushing's disease of the omentum”?
Bujalska, I. J., Kumar, S., & Stewart, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11222-8 · Cited by 753 · cited 1×
“The expression of this enzyme and of glucocorticoid receptors is significantly higher in omental fat than in subcutaneous fat (21, 22).”
BackgroundRohlmann, A., Gotthardt, M., Hammer, R. E., & Herz, J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1240 · Cited by 455 · cited 1×
“Inhibition of LRP by PIs may not account for hyperlipidemia, since inactivation of LRP in the liver of wild-type mice does not result in hyperlipidemia (28).”
BackgroundMetformin in the Treatment of HIV Lipodystrophy Syndrome: A Randomized Controlled Trial
Hadigan, C., Corcoran, C., Basgoz, N., Davis, B., Sax, P., & Grinspoon, S. (2000) · JAMA · doi:10.1001/jama.284.4.472 · Cited by 357
Self-citationEfficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes
Arioglu, E., Duncan-Morin, J., Sebring, N., Rother, K. I., Gottlieb, N., Lieberman, J., Herion, D., Kleiner, D. E., Reynolds, J., Premkumar, A., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-4-200008150-00009 · Cited by 303
Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome.
Grunfeld, C., Kotler, D. P., Shigenaga, J. K., Doerrler, W., Tierney, A., Wang, J., Pierson, R. N., & Feingold, K. R. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90536-7 · Cited by 286
Metadata
- Authors
- Koutkia, P., & Grinspoon, S.
- Venue
- Annual Review of Medicine
- Publisher
- Annual Reviews
- Published
- 2004-02-01
- Volume
- 55
- Issue
- 1
- Pages
- 303-317
- ISSN
- 0066-4219 (ISSN-L)
- 1545-326X
- OpenAlex
- W2160911126
- Cited by
- 179
- References
- 6
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HIV–Associated Lipodystrophy: Pathogenesis, Prognosis, Treatment, and Controversies. https://app.cochat.ai/papers/10.1146/annurev.med.55.091902.104412
- The paper
- Koutkia, P., & Grinspoon, S. (2004). HIV–Associated Lipodystrophy: Pathogenesis, Prognosis, Treatment, and Controversies. Annual Review of Medicine. https://doi.org/10.1146/annurev.med.55.091902.104412
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.